Keywords: symbicort, plus, beta, agonist, shows, promise, copd
Symbicort plus beta 2 agonist shows promise in COPD
Article | 10 July 2006
Anglo-Swedish drug major AstraZeneca says that a meta-data analysis of two studies of the firm's respiratory treatment Symbicort (budesonide/formoterol) ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- Is the diabetes market facing a blockbuster-free future?
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
